RCEL leads with 27.9% gain on EPS revision; other healthcare stocks follow
Five stocks detected by the EPS revision screener posted strong gains, led by RCEL (+27.9%) and AIRS (+13.8%). Each saw upward revisions to forward EPS growth estimates, with RCEL's estimate hitting 48.4% and TNDM's revised from 113.1% to 119.8%. The moves occurred despite limited company-specific news, underscoring the market's focus on earnings momentum.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| RCEL | Healthcare | 2026-07-14 | N/A | +27.9% |
| AIRS | Healthcare | 2026-07-13 | N/A | +13.8% |
| TNDM | Healthcare | 2026-07-16 | +6.8pp | +11.1% |
| CLMT | Basic Materials | 2026-07-13 | +8.1pp | +9.8% |
| IQ | Communication Services | 2026-07-12 | N/A | +8.8% |
Why did RCEL stock jump in July 2026?
RCEL jumped 27.9% from $4.02 to $5.14 after analysts revised its forward EPS growth estimate to 48.4% on July 14.
The revision coincided with the company announcing it would report Q2 2026 results on August 6, reinforcing positive sentiment. The stock gained steadily as the market priced in improved earnings expectations, with no other major news. The healthcare acute wound care sector has been attracting interest on margin recovery hopes.
RCEL EPS revision history → · Screener snapshot from 2026-07-14 →
FAQ: RCEL
Why did RCEL stock jump in July 2026?
RCEL jumped 27.9% from $4.02 to $5.14 after analysts raised its forward EPS growth estimate to 48.4% on July 14, reinforced by the announcement of upcoming Q2 2026 earnings.
What is RCEL's EPS growth estimate?
RCEL's forward EPS growth estimate for next year is 48.4%, reflecting improved profitability expectations.
Is RCEL a buy after the rally?
The 27.9% gain was driven by a positive EPS revision and earnings anticipation; investors should monitor the August 6 Q2 results for confirmation of the trend.
Why did AIRS stock jump in July 2026?
AIRS gained 13.8% from $4.20 to $4.78 after analysts raised its forward EPS growth estimate to 44.8% on July 13.
The healthcare sector saw broad interest in specialty providers, and AIRS's upward revision signaled improving profitability. No company-specific news emerged, but the market responded to the earnings trajectory. The stock continues to trade near multi-month highs.
AIRS EPS revision history → · Screener snapshot from 2026-07-13 →
FAQ: AIRS
Why did AIRS stock surge?
AIRS surged 13.8% from $4.20 to $4.78 after analysts revised its forward EPS growth estimate to 44.8% on July 13, signaling a strong profit turnaround.
What caused AIRS's price jump?
The price jump was triggered by an upward EPS revision for next year (44.8% growth) with no other news, reflecting market optimism about the company's earnings recovery.
What is AIRS's forward EPS growth?
AIRS's forward EPS growth estimate for next year is 44.8%, indicating a significant expected profit improvement.
Why did TNDM stock jump in July 2026?
TNDM jumped 11.1% from $16.29 to $18.10 after analysts raised its forward EPS growth estimate from 113.1% to 119.8% on July 16.
The revision reflects strong demand for its insulin pump systems and higher margin expectations. No news accompanied the move, but the steady upward drift underscores earnings momentum. The stock has gained 15% over the past month.
TNDM EPS revision history → · Screener snapshot from 2026-07-16 →
FAQ: TNDM
Why did TNDM stock rise recently?
TNDM rose 11.1% from $16.29 to $18.10 after analysts increased its forward EPS growth estimate from 113.1% to 119.8% on July 16.
What is TNDM's EPS revision?
TNDM's forward EPS growth estimate was revised upward by 6.8 percentage points to 119.8% on July 16.
Is TNDM a good investment after the gain?
The 11% gain came on a positive EPS revision with strong growth rates; investors should consider the high growth estimate but watch for diabetes market trends.
Why did CLMT stock jump in July 2026?
CLMT rose 9.8% from $39.58 to $43.44 after analysts revised its forward EPS growth estimate from 197.4% to 205.5% on July 13.
The specialty chemical and renewable fuels company is benefiting from favorable energy prices and cost improvements. The upward revision suggests continued operational momentum. No specific news catalysts were reported in the window.
CLMT EPS revision history → · Screener snapshot from 2026-07-13 →
FAQ: CLMT
Why did CLMT stock climb?
CLMT climbed 9.8% from $39.58 to $43.44 after analysts raised its forward EPS growth estimate from 197.4% to 205.5% on July 13.
What is CLMT's EPS growth estimate?
CLMT's forward EPS growth estimate is 205.5%, reflecting very strong expected earnings growth next year.
What drove CLMT's rally?
The rally was driven by an upward EPS revision (8.1 percentage point increase) with no other news, hinting at improved profitability in energy and specialty materials.
Why did IQ stock jump in July 2026?
IQ gained 8.8% from $1.13 to $1.23 after analysts set its forward EPS growth estimate at 1232.9% on July 12.
The extreme estimate indicates a sharp earnings rebound from a low base, typical for turnaround situations. The move aligned with sector-wide optimism in Chinese tech stocks. No company-specific news emerged, but the revision itself acted as a catalyst.
IQ EPS revision history → · Screener snapshot from 2026-07-12 →
FAQ: IQ
Why did IQ stock jump?
IQ jumped 8.8% from $1.13 to $1.23 after analysts established a forward EPS growth estimate of 1232.9% on July 12, signaling a dramatic earnings turnaround.
What is iQIYI's EPS growth forecast?
iQIYI's forward EPS growth estimate is 1232.9% next year, reflecting expectations of a strong recovery from currently depressed earnings.
Is IQ a buy after the surge?
The 8.8% gain was fueled by an extreme EPS revision; while the growth estimate is high, investors should assess the sustainability of the turnaround.
Today's performers signal that investors are heavily rewarding earnings momentum, particularly in healthcare, as companies with improving profit outlooks see rapid price appreciation independent of news catalysts. The breadth of revisions across sectors suggests a market increasingly focused on fundamental improvements.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →